PainReform Ltd Stock News

As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel , May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on...

TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The project will utilize PainReform's proprietary DeepSolar™ platform, an AI-powered optimization solution designed to enhance operational efficiency and energy yield a...

TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven so...

TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of the DeepSolar activities, today provided a business update for the year ended December 31, 2024.

Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Comp...

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.